Annals of Lung Cancer

 ISSN: 2643-5713

Annals of Lung Cancer

About Journal


Annals of Lung Cancer is an international, open access, peer reviewed journal focusing to publish various types, stages, causes, signs and symptoms, diagnosis, prognosis and survival rate, treatment and management of Lung Cancers. This journal brings novel insights concerning all the clinical, experimental, translational and basic science of malignancies of the lung and chest region. All the published content in the journal are freely accessible without any restriction under Creative Commons Attribution License.

The journal invites various article formats such as original, reviews, cases, clinical images, communications and other short article types providing in depth information related but not limited to prevention, epidemiology and etiopathology, basic biology, cytopathology, clinical assessment, surgery, chemotherapy, radiotherapy, possible treatment modalities, possible biomarkers for early detection, other treatment modalities and survivals of lung cancer.

The journal publishes only selective articles after thorough peer review processing of the manuscripts by international research experts.


Editorial Board



Dr. Paul H Hartel

Medical Director
Telepathology and Clinical Laboratory Medicine
Grafton City Hospital
United States of America


Dr. Oscar Juan Vidal

Professor
Medical Oncology Department
Universidad Catolica de Valencia San Vicente Martir.
Valencia, Spain
Tel: +34-961265877


Dr. Gaetano Bertino

Professor
Internal Medicine and Surgery
University of Catania
Italy
Tel: +390953781573


Dr. Xuexia Wang

Associate Professor
Division of Biostatistics
University of North Texas
United States of America
Tel: 215-776-9458


Dr. Vianey Rodriguez

Associate Professor
Tissue and Cell Biology Department
Medical School of UNAM
United States of America
Tel: 52-55-56-23-21-83


Dr. Young Ho Seo

Associate Professor
College of Pharmacy
Keimyung University
South Korea
Tel: 053-580-6639


Submit your manuscript to this journal through online or email us at editorialoffice@scholars.direct


Latest Articles

Research Article

Dosimetric Implications of Number of Breathing Phases Used in the Definition of Internal Target Volume [ITV] in the Treatment of Non-Small Cell Lung Cancers Using Stereotactic Body Radiation Therapy (SBRT)

Determination of intrafraction motion in stereotactic body radiation therapy (SBRT) of non-small-cell lung cancer (NSCLC) usually involves generating... Read more

10.36959/825/572

Research Article

Impact of an Onsite Endobronchial Ultrasound Program on the Time to Treatment of Cancer in Veterans

Endobronchial ultrasound (EBUS) is commonly employed in the diagnostic evaluation of pulmonary nodules and for mediastinal staging of lung cancer. We ... Read more

10.36959/825/581

Editorial

Nucleobindin-2 mRNA level is down regulated in KRAS-mutation lung cancer cell lines compared with EGFR/BRAF/KRAS wild-type lung cancer cell lines

All participants understand that the information will be published anonymously, but that full anonymity cannot be guaranteed. We understand that the t... Read more

10.36959/825/580

Original Research

Lobaplatin or Cisplatin Plus Etoposide for Treating Extensive Stage Small Cell Lung Cancer

The EL and EP groups did not differ substantial in objective response rate, hospital stay, or rate of leukocyte and platelet decrease. In the two grou... Read more

10.36959/825/579

Original Research Article

Effect of Respirable Coal Mine Dust and Quartz on Lung Function Parameters of German Coalminers: A Longitudinal Study 1974-2004

Longitudinal inception cohort study (1974-2004) on miners who started working underground at two coal mines in Germany between 1974 and 1979. From the... Read more

10.36959/825/578

Original Article

The Risk of Developing Coal Workers' Pneumoconiosis in a German Inception Cohort of Coal Miners of Ruhr Area - Results after 30 Years of Follow-up

Comprehensive dust control and health protection measures have been implemented to prevent coal workers' pneumoconiosis (CWP) in German collieries sin... Read more

10.36959/825/577

Research Article

Survival and Grades vs. Costs and Values of Nivolumab in Cancer; the Impact of PD-L1 Positivity

Nivolumab (Nivo) is a programmed death receptor-1 immune check point antibody widely used in cancer.... Read more

10.36959/825/576

Research Article

Survival and Values of the Immune Check Point Inhibitors in Non- Small-Cell Lung Cancer

The efficacy and safety of the Immune Check Point Inhibitors (ICPI) have been well documented. Their costs and values have received lesser attention.... Read more

10.36959/825/575

Case Study

Pseudoprogression in Non-Small Cell Lung Cancer Brain Metastases Attributable to the Anti-PD-1 Antibody Nivolumab

Pseudoprogression is a challenging obstacle in the interpretation of therapeutic response to radiation and chemotherapies for metastatic brain lesions... Read more

10.36959/825/574

REVIEW ARTICLE

Radiation Therapy in the Treatment of Small Cell Lung Cancer

Small Cell Lung Cancer (SCLC) represents between 13-15% of all lung cancers; however is the fifth leading cause of cancer death worldwide. SCLC progno... Read more

10.36959/825/573